Latest Harness Therapeutics News & Updates

See the latest news and media coverage for Harness Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Harness Therapeutics

Biotechnology company developing precision therapies for neurodegenerative diseases

harnesstx.com

Headquarters: Cambridge, United Kingdom
Founded year: 2023
Company type: Private company
Number of employees: 31–50
Industry: Biotechnology & Medical Research

Last updated February 16

Latest news about Harness Therapeutics

In short: Harness Therapeutics nominated HRN001 for Huntington’s, launched MISBA Duo, and won an MJFF Parkinson’s grant.

Company announcements

February 16 Harness Therapeutics

Harness Therapeutics nominates HRN001 for Huntington’s disease

HRN001 is a first-in-class antisense oligonucleotide upregulating FAN1. The company forms a Clinical Advisory Board to guide clinical progression in 2027.

February 1 Harness Therapeutics

Harness Therapeutics appoints Meenu Chhabra Karson as Board Chair

She brings over 20 years of biopharma experience, including fundraising, partnerships, and leadership roles at Samsara Therapeutics and others. Her expertise supports growth in neurodegenerative therapeutics.

October 6, 2025 Harness Therapeutics

Harness Therapeutics announces MISBA Duo platform launch

The platform enables simultaneous upregulation and downregulation of two targets. It collaborates with Ono Venture Investment on an R&D program for a rare triplet repeat disorder.

October 1, 2025 Harness Therapeutics

Harness Therapeutics appoints experts to its Scientific Advisory Board

The SAB includes leaders in genetics, biology, and Huntington’s disease to guide HRN001 development and pipeline expansion. CTA-enabling studies for HRN001 start in 2025.

Media coverage

February 16 BioSpace

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board - BioSpace

Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference · Cambridge, UK, 16 February 2026: Harness Therapeutics...

October 6, 2025 WTNH

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

R&D programme with Ono Venture Investment builds on insights from first generation platform, and targets an undisclosed rare triplet repeat disorder Cambridge, UK, 06 October...

February 19, 2025 MENAFN

Harness Therapeutics Appoints Experienced R&D Executive And Physician-Scientist, Dr Paulo Fontoura, As Non-Executive Director

(MENAFN- GlobeNewsWire - Nasdaq) Dr Paulo Fontoura brings 20 years' experience of working in the pharma industry, with the most recent 16 years focusing on...

February 19, 2024 KHON2

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the...

Never miss news about Harness Therapeutics

Track Harness Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Harness Therapeutics competitors & trending companies

Browse news for competitors to Harness Therapeutics and other trending companies.